Dr. Reddy’s Laboratories Ltd ADR (RDY)
Exchange: USA Stocks • Country: India • Currency: USD • Type: Common Stock • ISIN: US2561352038
Dr. Reddy's Laboratories Ltd ADR (NYSE: RDY) is a global pharmaceutical company that operates in three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The company manufactures and markets prescription and over-the-counter pharmaceutical products under various brand names worldwide.
The Global Generics segment is involved in manufacturing and selling both branded and generic pharmaceutical products with therapeutic equivalence. They also have a biologics business within this segment.
The PSAI segment focuses on manufacturing active pharmaceutical ingredients and intermediates that are key components of finished pharmaceutical products. They offer contract research services and cater to specific customer requirements for manufacturing active pharmaceutical ingredients and steroids.
In addition to these segments, the Others segment of Dr. Reddy's Laboratories is dedicated to developing therapies in areas like oncology and inflammation, as well as researching and developing differentiated formulations. They also provide digital healthcare services and IT-enabled business support.
The company's therapeutic categories cover a wide range including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited has been in operation since 1984 and is headquartered in Hyderabad, India. To learn more, you can visit their website at https://www.drreddys.com.
Drawdown (Underwater) Chart
RDY Stock Overview
Market Cap in USD | 11,846m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 2001-04-11 |
RDY Stock Ratings
Growth 5y | 5.30 |
Fundamental | 72.9 |
Dividend | 7.77 |
Rel. Performance vs Sector | 1.47 |
Analysts | 3.00/5 |
Fair Price Momentum | 75.06 USD |
Fair Price DCF | 4818.68 USD |
RDY Dividends
Yield 12m | 1.29% |
Yield on Cost 5y | 2.38% |
Dividends CAGR 5y | 11.45% |
Payout Consistency | 94.1% |
RDY Growth Ratios
Growth 12m | 25.60% |
Growth Correlation 12m | 61% |
Growth Correlation 3m | -35% |
CAGR 5y | 12.98% |
Sharpe Ratio 12m | 1.02 |
Alpha vs SP500 12m | 10.87 |
Beta vs SP500 5y weekly | 0.46 |
ValueRay RSI | 69.52 |
Volatility GJR Garch 1y | 22.79% |
Price / SMA 50 | 1.57% |
Price / SMA 200 | 7.49% |
Current Volume | 224.3k |
Average Volume 20d | 190.2k |
External Links for RDY Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 07, 2024, the stock is trading at USD 75.21 with a total of 224,293 shares traded.
Over the past week, the price has changed by +1.06%, over one month by +1.97%, over three months by +3.24% and over the past year by +25.60%.
According to ValueRays Forecast Model, RDY Dr. Reddy’s Laboratories Ltd ADR will be worth about 81.1 in May 2025. The stock is currently trading at 75.21. This means that the stock has a potential upside of +7.79%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 79.9 | 6.18 |
Analysts Target Price | 70.1 | -6.78 |
ValueRay Target Price | 81.1 | 7.79 |